Andrew J K Ostor
Overview
Explore the profile of Andrew J K Ostor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Van den Bosch F, Ostor A, Wassenberg S, Chen N, Wang C, Garg V, et al.
Rheumatol Ther
. 2017 Apr;
4(1):85-96.
PMID: 28361468
Introduction: Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a proprietary patient support program (PSP, AbbVie Care). The main objective of this study was to...
12.
Rischin A, Ostor A
Inflammopharmacology
. 2017 Mar;
25(2):177-184.
PMID: 28265837
Biologic agents have become indispensable in the management of autoimmune disease particularly rheumatological conditions. The lives of countless individuals have been improved following treatment with these drugs. Unfortunately, their cost...
13.
Ye W, Fifield M, Ostor A
J Clin Rheumatol
. 2017 Feb;
23(2):125-126.
PMID: 28225518
No abstract available.
14.
Cooles F, Anderson A, Drayton T, Harry R, Diboll J, Munro L, et al.
Arthritis Res Ther
. 2016 Dec;
18(1):302.
PMID: 27993172
Background: Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant...
15.
Negoescu A, Ostor A
Rheumatol Ther
. 2016 Oct;
2(1):17-31.
PMID: 27747493
Rheumatoid arthritis (RA) is a chronic systemic autoimmune condition which affects approximately 1% of the adult population worldwide and is characterized by joint inflammation, with extra-articular features being common. Interleukin...
16.
Maki-Petaja K, Day L, Cheriyan J, Hall F, Ostor A, Shenker N, et al.
J Am Heart Assoc
. 2016 Feb;
5(2).
PMID: 26896473
Background: Rheumatoid arthritis is a systemic inflammatory condition associated with increased cardiovascular risk that may be due to underlying endothelial dysfunction and subsequent aortic stiffening. We hypothesized that supplementation with...
17.
Shaikh M, Ostor A
Practitioner
. 2016 Feb;
259(1788):21-4, 2-3.
PMID: 26882775
In the UK, low back pain is the most common cause of disability in young adults and every year 6-9% of adults consult their GP about back pain. A thorough...
18.
Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, et al.
Adv Ther
. 2015 Nov;
32(11):983-1028.
PMID: 26547912
Background: Non-adherence impacts negatively on patient health outcomes and has associated economic costs. Understanding drivers of treatment adherence in immune-mediated inflammatory diseases is key for the development of effective strategies...
19.
Nisar M, Rafiq A, Ostor A
Clin Rheumatol
. 2015 Oct;
34(12):2141-5.
PMID: 26497501
Biologic therapies have resulted in a sea change in the management of inflammatory arthritis; however, a higher risk of opportunistic infection, particularly tuberculosis (TB), is well recognised. This has led...
20.
Bykerk V, Ostor A, Alvaro-Gracia J, Pavelka K, Ivorra J, Graninger W, et al.
Clin Rheumatol
. 2015 May;
34(7):1321.
PMID: 25943189
No abstract available.